
|Articles|July 28, 2015
Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Cancer Care and Education in the Era of Precision Oncology
2
Sub-Q Mosunetuzumab Wins FDA Approval in R/R Follicular Lymphoma
3
ADC Receives Orphan Drug Designation in Small Cell Lung Cancer
4
Being a “Last Responder” to Patients With Cancer With Melinda Mayorga
5































































































